Magnetic resonance imaging (MRI) is an important tool in the diagnosis of many cancers. However, clinical gadolinium (Gd)-based MRI contrast agents have limitations, such as large doses and potential side effects. To address these issues, we developed a hydrogen-bonded organic framework-based MRI contrast agent (PFC-73-Mn). Due to the hydrogen-bonded interaction of water molecules and the restricted rotation of manganese ions, PFC-73-Mn exhibits high longitudinal relaxation r 1 (5.03 mM -1 s -1 ) under a 3.0 T clinical MRI scanner. A smaller intravenous dose (8 μmol of Mn/kg) of PFC-73-Mn can provide strong contrast and accurate diagnosis in multiple kinds of cancers, including breast tumor and ultrasmall orthotopic glioma. PFC-73-Mn represents a prospective new approach in tumor imaging, especially in early-stage cancer.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- diffusion weighted imaging
- early stage
- room temperature
- transition metal
- metal organic framework
- high resolution
- low dose
- papillary thyroid
- water soluble
- high dose
- dual energy
- quantum dots
- cross sectional
- ionic liquid
- mass spectrometry
- sentinel lymph node
- childhood cancer
- rectal cancer
- locally advanced